Breakthrough in purification
Shimadzu’s new ASAPrep for RPC (“Automated Scale-up from Analytical to Preparative conditions for Reversed Phase Purification”) predicts success and failure of purification automatically and determines an optimal preparative condition.
The quality of purification processes in, e.g. medicinal chemistry, has been highly dependent on the chromatographers’ skill. Large pharmaceutical companies are capable of synthesizing hundreds of new compounds per day, but they cannot provide high purity compounds in sufficient amounts for High Throughput Screening (HTS), nor does the speed of purification match NCE (New Chemical Entities) synthesis.
Shimadzu’s new ASAPrep for RPC (“Automated Scale-up from Analytical to Preparative conditions for Reversed Phase Purification”) predicts success and failure of purification automatically and determines an optimal preparative condition. Based on an algorithm, the preparative method is created automatically, and users save time while increasing throughput. The algorithm calculates optimal initial organic mobile phase concentration in preparative scale using the retention time acquired by LC-PDA-MS measurement and judging of the difference between success and failure of purification.
ASAPrep for RPC runs on an LCMS-2010 single quadrupole system in analytical and preparative mode.
For more information please visit www.shimadzu.eu
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
